866-897-8297

Call Is Confidential & Toll Free

Glyxambi

Glyxambi is a DPP -4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Two pharmacological characteristics that sets glyxambi apart from other DPP -4 inhibitors is that it has a non-linear pharmacokinetic profile and is not primarily eliminated by the renal system. FDA approved on May 2, 2011.

Glyxambi is a more potent inhibitor of DPP-4 than other drugs that belong to the same class with an IC50 of 1 nM. In comparison, sitagliptin, saxagliptin, and vildagliptin have an IC50 of 19, 50, and 62 nM respectively. A dose of 2.5 and 5 mg reduces the activity of DPP-4 by 72.7% and 86.1% from baseline respectively in healthy male subjects. In diabetes patients, a dose of 5 and 10 mg inhibits >90% of DPP-4. Glyxambi is also selectively inhibits DPP-4 as indicated by the lack of DPP-8 or DPP-9 inhibition at therapeutic exposures in vitro.

Imprints


Drug: Glyxambi
Strength: Empagliflozin 10 Mg / Linagliptin 5 Mg
Pill Imprint: 10/5 Logo
Color: Yellow
Shape: Three-sided

View Images & Details

Drug: Glyxambi
Strength: Empagliflozin 25 Mg / Linagliptin 5 Mg
Pill Imprint: 25/5 Logo
Color: Pink
Shape: Three-sided

View Images & Details
Disclaimer: We strive to ensure that the content on pilladdictions.com is current and factual at the time it was written. However, because new information and discoveries are always becoming available, we are not making any representations or warranties with respect to this content. Please always rely on the guidance of your physician for information about the drugs you are taking and the impacts they may or may not have on your health.

Questions About Prescription Drug Addiction?

(888) 740-2069

Questions About Prescription Drug Addiction?